Erectile dysfunction (ED) has been revolutionized during the last two decades, as several
treatment options are available today. Phosphodiesterase type 5 (PDE5) inhibitors …

Importance to the field: Since sildenafil was introduced 10 years ago, highly selective
phosphodiesterase type 5 inhibitors (PDE5i) have changed the medical management of …

Aims To review recent (since 2007) developments on the utilization of PDE5I in clinical
practice. The focus of this manuscript is on the use of PDE5I for sexual concerns. Also …

OBJECTIVE: Review the literature on phosphodiesterase type 5 inhibitors (PDE5-Is),
addressing critical issues in their current and future use, assessing unanswered questions …

OBJECTIVE To review the pharmacologic and clinical trial data of the Food and Drug
Administration–approved phosphodiesterase 5 (PDE5) inhibitors for the treatment of erectile …

PDE-5 inhibitors were originally studied in cardiovascular indications but were later
developed and approved for on-demand treatment of erectile dysfunction (ED). A few years …

Erectile dysfunction (ED) is a common medical condition that has a negative impact on men
and their partners. The field has revolutionised over the last two decades and more …

Erectile dysfunction (ED) has multifactor pathogenesis, with neurological, vascular,
endocrinological and psychogenic components described. However, about 50-85% of ED …

Introduction Erectile dysfunction (ED) is a very common multidimensional disorder affecting
men worldwide. Physical illness, reaction to life stresses, or an unhappy couple relationship …

J Clin Hypertens (Greenwich). 2012; 14: 644–649.© 2012 Wiley Periodicals, Inc.
Phosphodiesterase 5 (PDE‐5) inhibitors are selective blockers of PDE‐5, which catalyzes …